High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

This study has been completed.
Sponsor:
Collaborators:
AstraZeneca
Massachusetts General Hospital
Information provided by (Responsible Party):
David M. Jackman, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00372515
First received: September 6, 2006
Last updated: April 25, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)